Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight ...

Altimmune shares cratered nearly 60% on Thursday after its experimental obesity drug did not significantly improve liver ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis ...

Altimmune said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease. The drug, pemvidutide, showed a ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety ...

Fatty liver disease, caused by the accumulation of fat in the liver, is estimated to affect one in four people worldwide. If ...

Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...

Altimmune, Inc.’s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, liver health, and cardiovascular support. Their Phase 2 MOMENTUM trial ...

Researchers in Japan created an AI that can detect fatty liver disease from ordinary chest X-rays—an unexpected and low-cost ...

An estimated 15 million Americans -- 1 in 20 adults-- suffer from fatty liver disease, also known as metabolic dysfunction-associated steatohepatitis (MASH), researchers said in background notes.